ABSTRACT: The diameter of biodegradable particles used to coencapsulate immunostimulants and subunit vaccines affects the magnitude of memory CD8 + T cells generated by systemic immunization. Possible effects on the magnitude of CD8 +
■ INTRODUCTION
To be effective, prophylactic vaccines must generate long-lived protective adaptive immune responses against a given pathogen at levels that correlate with a defined clinical end point such as a decrease in the incidence of infectious disease in a specific population. 1, 2 Most licensed vaccines to date generate longlived plasma B cells that secrete protective pathogen-specific antibodies at levels that correspond to protection against extracellular pathogens or pathogen-derived toxins. 3−5 Neutralizing antibodies, however, are insufficient for protection against pathogens that undergo frequent changes to their surface antigens and/or predominantly remain within host cells during their life cycle. 3 For these pathogens, there is extensive preclinical and, to a lesser extent, clinical data that long-lived memory CD4 + or CD8 + T cells are required for reduction, clearance, and subsequent control of infection 1, 3, 6 although isotypes of pathogen-specific antibodies may further increase the efficacy of protective T cell memory recall responses. 7 Thus, it is likely that efficacious vaccines against antibody-resistant pathogens must additionally generate long-lived protective memory T cells.
Vaccines composed of live attenuated pathogens are the most likely to generate long-lived protective memory T cells after systemic or mucosal administration at levels that correlate with protection against the wild type pathogen. 8 Live attenuated vaccines, however, require a long time to develop, seldom produce a safe and stable vaccine, may not cross-protect against different strains of the same pathogen, have the potential for pathogenic reversion, and are not an option for pathogens that cannot be grown in culture. 8−10 The limitations of live attenuated vaccines can potentially be overcome by subunit vaccines composed of proteins ("recombinant protein vaccines") or peptide epitope(s) ("synthetic peptide vaccines") identified from regions of the pathogen that generate protective adaptive immune responses. 11, 12 Most proteins and peptides, however, do not generate sufficient levels of long-lived T cells because they are rapidly cleared from the administration site, inefficiently delivered to antigen-presenting cells (APCs), and lack immune stimulating moieties from the original pathogen that activate APCs. 11, 12 Coencapsulating appropriate immunostimulants and protective proteins or peptides (i.e., subunit vaccines) within nanoscale-sized particles composed of biodegradable polymers 13 is a promising, well-established approach to increase the generation of long-lived T cells by subunit vaccines after systemic or mucosal immunization.
14 It provides several advantages including decreased vaccine degradation and clearance, increased immunostimulation at the administration site, increased levels and duration of epitope presentation and cross-presentation by activated APCs, and increased mucosal and systemic adaptive immune responses following mucosal administration. 15−25 The diameter of nanoscale biodegradable particles is a key dosage form parameter 26−29 that potentially affects the magnitude of CD4 + and CD8 + T cells as well as Th1/Th2 memory subsets of CD4 + T cells generated by coencapsulated immunostimulant/subunit vaccines after systemic immunization. 30, 31 It remains unclear, however, whether the diameter of coencapsulating biodegradable particle affects the generation of mucosal and systemic memory T cells by coencapsulated immunostimulants/subunit vaccines after mucosal immunization. Furthermore, memory T cells continue to be further distinguished based on the expression of cell surface markers (cell surface phenotype) or the release of one or multiple cytokines after exposure to protective epitopes (functional phenotype) that collectively relate more closely to T cell functions that are critical for vaccine efficacy such as long-term survival, recall response upon reinfection with different pathogens, and cytolytic activity. 32, 33 Differential protection against several pathogens by memory subsets of CD4 + and CD8 + T cells has also been reported after adoptive transfer in murine models of infectious disease. 34 Thus, it is important to determine if the diameter of encapsulating biodegradable particle potentially affects not only the magnitude of vaccinegenerated T cells but also established and emerging memory T cell subsets that potentially correlate more strongly with protection against the targeted pathogen. 6 We previously developed the novel host-derived peptide immunostimulant, EP67, 35 based on the last 10 amino acids of the C-terminal of human complement component 5a (C5a) that minimizes the toxic proinflammatory side effects of the C5a parent peptide by selectively activating APCs over neutrophils. 35, 36 Systemic immunization with vaccines composed of EP67 conjugated to peptides, intact proteins, or attenuated pathogens generates Th1-biased humoral and cellular immune responses in mice presumably, in large part, by simultaneously activating DCs and increasing subsequent processing and presentation of conjugated immunogens through the binding and activation of the C5a receptor (C5aR/CD88). 37 We also recently found that respiratory immunization with a CTL peptide vaccine composed 1/1 (w/ w) with EP67 directly conjugated to the dominant protective MCMV CTL epitope pp89 or subdominant CTL epitope M84 increases protection against respiratory infection with MCMV in BALB/c mice, indicating that EP67 can act as a mucosal adjuvant. 38 In this study, we conjugated EP67 to the C-terminal of pp89 through a lysosomal protease-labile double arginine linker (pp89-RR-EP67) and intranasally administered PBS (50 μL), PBS containing unencapsulated pp89-RR-EP67 (50 μg), or PBS containing the same dose of pp89-RR-EP67 (50 μg) encapsulated in PLGA 50:50 micro-(∼5.4 μm) or nanoparticles (∼350 nm) to naive female BALB/c mice. We then compared the total magnitude, effector/central memory (CD127/KRLG1/CD62L), and IFN-γ/TNF-α/IL-2 secreting subsets of pp89-specific CD8 + T cells in the lungs (mucosal) and spleen (systemic) as well as protection against primary respiratory infection with MCMV 21 days after respiratory immunization.
■ EXPERIMENTAL SECTION
Peptides. An MCMV CTL epitope from pp89 ( 168 YPH-FMPTNL 176 ) that is protective in BALB/c mice 39 Figure S1 ). Encapsulation of pp89-RR-EP67 in Biodegradable Micro-and Nanoparticles. The CTL peptide vaccine (pp89-RR-EP67) was encapsulated in biodegradable microparticles (MP) or nanoparticles (NP) at 5 wt % theoretical loading by the emulsification/solvent evaporation (ESE) method. 22 The primary water−oil emulsion (W 1 /O) was formed by adding a sterile PBS (D-PBS without Mg 2+ or Ca 2+ ) "water" solution containing pp89-RR-EP67 (20 mg/mL; 0.5 mL) to a dichloromethane (DCM) "oil" solution containing ester-terminated 50:50 poly D,L-lactic-co-glycolic acid (PLGA 50:50; research grade; inherent viscosity 0.38 dL/g; Lactel, Pelham, AL; 100 mg/mL DCM; 2 mL) in a glass test tube (16 × 100 mm) and homogenized at 13,500 rpm for 1 min (Fisher Powergen 500 homogenizer) to form microparticles or sonicated for 30 s at 50% amplitude (Misonix Sonicator 3000 with model 419 tapered microtip horn with 0.125 in. diameter tip) to form nanoparticles. The W 1 /O emulsion was immediately transferred to a PVA solution (1% v/v poly(vinyl alcohol) [70% hydrolyzed; 30,000−70,000 Da; Sigma-Aldrich] in dH 2 O; 8 mL) in a 20 mL scintillation glass vial and sonicated or homogenized as described for the primary emulsion to form the secondary water−oil−water emulsion (W 1 /O/W 2 ). The W 1 /O/W 2 emulsion was then transferred to a larger volume of 1% v/v PVA solution (32 mL) in a 50 mL glass beaker and stirred (1000 rpm using a 2.5 cm, 3.97 g Teflon-coated, smooth stirring bar with molded-on pivot rings) for 4 h to fully remove DCM. Hardened NP and MP were pelleted (25,000 RCF or 20,000 RCF, respectively, for 15 min at 4°C) and then resuspended and pelleted 3× using dH 2 O (20 mL) to remove residual PVA. Washed particles were resuspended in dH 2 O (10 mL) in a preweighed 20 mL scintillation vial, flash frozen in liquid N 2 , lyophilized for 48 h, and stored at −20°C in a capped vial sealed with parafilm.
pp89-RR-EP67 Loading in PLGA Particles. Peptide loading was determined as described with modification. 41 Particles (∼10 mg) were equilibrated to rt, added to DMSO (0.5 mL) in an 8 mL glass vial, and incubated for 1 h on with constant shaking. A solution of 0.05 M NaOH/0.5% SDS in dH 2 O (5 mL) was added to the DMSO/particle solution, and the entire solution was stirred (400 rpm) in the capped vial for 1 h. Undissolved polymer was pelleted (10,000 RCF, 10 min), and average peptide concentration in the supernatant was determined by Pierce Micro BCA assay (Thermo Scientific) with pp89-RR-EP67 as the standard and (1/10) DMSO/0.05 N NaOH (0.05% SDS) as the diluent. Average peptide loading (μg peptide/mg particles ± SD (n = 3) was calculated as Diameter and Zeta-Potential of PLGA Particles. Average hydrodynamic diameters and zeta-potentials ± SD (n = 3 independent samples from the same batch) of the particles were measured in dH 2 O (0.5 mg/mL) at 25°C using a ZetaSizer Nano ZS (Malvern Instruments, Malvern, U.K.) equipped with a He−Ne laser (λ = 633 nm) as the incident beam.
Peptide Burst Release from PLGA Particles. PLGA particles (∼10 mg) were added to a centrifuge tube (2 mL), resuspended in PBST (PBS and Tween-20 [0.05% v/v]; 1 mL), vortexed for 20 s, and incubated at 37°C (Vortemp 56 Shaking Incubator) with shaking (200 rpm/min). Supernatants (10,000 RCF, 5 min) were collected after 24 h and stored (−20°C), and the concentration of pp89-RR-EP67 was determined as described above using PBST as the diluent. Average percent of pp89-RR-EP67 ± SD (n = 3 independent samples from the same batch) released from the particles was calculated as where extraction volume was the volume of Freezing Media used for MCMV extraction (1 mL for lungs, spleen, and salivary glands; 2 mL for liver) and mass of tropic organ was the mass of the isolated organ used in the extraction. Average MCMV PFU/g ± SD (n = 5 mice) values were compared to PBS by one-way ANOVA with uncorrected Fisher's LSD test. Plaque assays were repeated at least once to confirm the reproducibility of the results.
Respiratory Immunization. Sterile PBS alone (50 μL) or sterile PBS containing pp89-RR-EP67 alone (50 μg) or pp89-RR-EP67 (50 μg equivalent) encapsulated in MP or NP on days 0 and 7 was administered intranasally to naive female BALB/c mice (4-weeks old; n = 4) by anesthetizing with isoflurane in a drop jar, holding upright, and alternating drops between nares with a 200 μL pipet. Intranasal (i.n.) administration of 50 μL is expected to deposit vaccine primarily in the nasal cavity and lungs (i.e., respiratory immunization). To isolate lymphocytes, lungs were transferred into a sterile 6-well cell culture plate (one lung/well), minced into small pieces with a sterile scalpel (#15, Bard-Parker), and incubated in cRPMI (6 mL) containing Collagenase IV (2 mg/mL; Worthington Enzymes) at 37°C for 1 h with shaking (Vortemp 56 shaking incubator, 200 rpm). Digested lungs were triturated by pipetting (18G needle) (3×) and filtered through a sterile 70 μm cell strainer into a sterile 15 mL conical tube. Filtered cells were pelleted (400 RCF, 4°C, 5 min), resuspended in RPMI 1460 (5 mL), layered onto Lympholyte-M (Cedarlane Laboratories; 5 mL) in a sterile 15 mL conical tube using a sterile Pasteur pipet, and centrifuged (1500 RCF without brakes, 4°C, 20 min). Lymphocytes were collected from the interphase with a sterile Pasteur pipet, transferred to a sterile 15 mL conical tube, resuspended in sterile D-PBS (10 mL), pelleted (500 RCF, 4°C, 5 min), resuspended in cRPMI (1 mL), and stored on ice for later use.
To isolate splenocytes, spleens were transferred to a sterile 70 μm strainer inserted into a sterile 50 mL conical tube, cut into at least 3 to 4 small pieces with a sterile scalpel (#15, BardParker), and then gently pushed through the cell strainer with the rubber end of a sterile syringe plunge while adding RPMI 1640 (30 mL). The strainer was rinsed with additional RPMI (10 mL), and filtered cells were diluted to 50 mL with sterile D-PBS, pelleted (500 RCF, 4°C, 10 min), resuspended in RBC lysis buffer (ACK Lysing Buffer; 4 mL), and incubated at rt for 5−7 min. After incubation, cRPMI (10 mL) was added, and the entire solution was triturated with a sterile 5 mL pipet to obtain a single cell suspension and passed through a 40 μm cell strainer into a sterile 50 mL conical tube. Filtered cells were then diluted with sterile D-PBS to 50 mL, pelleted (500 RCF, 4°C
, 10 min) (2×), and resuspended in cRPMI (3 mL), cell count and viability were determined by trypan blue exclusion (Cellometer Auto T4, Nexcelom Biosciences), and the cells were then stored on ice for later use.
Surface Phenotype Subsets of Epitope-Specific CD8 + T Cells. The surface phenotype of epitope-specific CD8a + cells was determined 21 days postimmunization by flow cytometry. Lymphocytes (lungs) and splenocytes were isolated as described above, diluted in cRPMI (10 7 cells/mL), and plated in a sterile 96-well plate (0.1 mL/well; 10 6 cells). An additional single well was plated (0.1 mL) from PBS immunizations as an unstained FACS control. Cells were pelleted (400 RCF, 5°C, 5 min), resuspended in sterile PBS (0.1 mL), pelleted (400 RCF, 5°C, 5 min), resuspended in sterile PBS (0.1 mL) containing Zombie Yellow (1 μL, BioLegend), incubated at rt for 15 min in the dark, and then pelleted (400 RCF, 5°C, 5 min). Potential Fixed cells were analyzed on a BD LSR II flow cytometer (Becton and Dickinson, La Jolla, CA). Instrument compensation settings were adjusted using BD CompBeads (BD Biosciences) with staining antibodies. Maximum number of events (total cells from each sample) was acquired and analyzed by FlowJo software (Tree Star, Ashland, OR, USA). The lymphocyte population was gated based on FSC (A) vs SSC (A) plots and used for subsequent analysis (at least 15,000 CD8a + cells from the lungs and at least 10,000 CD8a + cells from the spleen). Average proportions of CD8a + cells with the indicated cell surface staining ± SD (n = 4 mice) were compared by ordinary one-way ANOVA with uncorrected Fisher's LSD test or by two-tailed unpaired t-test as indicated.
Epitope-Responsive Subsets of CD8 + T Cells. The proportion of pp89-responsive CD8a + T cells in the lungs and 6 cells; BioLegend) and then analyzed by flow cytometry as described above. The lymphocyte population was initially gated based on FSC (A) vs SSC (A) plots and used for subsequent analysis. Average proportions of indicated cell populations in the spleen ± SD (n = 3 mice) were compared to PBS by ordinary one-way ANOVA with uncorrected Fisher's LSD test.
Respiratory Challenge with Salivary Gland-Derived MCMV. Twenty-one days after the final immunization (day 28), a sublethal amount of P1-SGV (5 × 10 3 PFU) was administered in the same manner as the vaccines. Intranasal administration in 50 μL is expected to deposit virus primarily in the nasal cavity and lungs (i.e., respiratory challenge). 43 Average MCMV PFU/g ± SD (n = 5 mice) in the salivary glands of each treatment group were compared to PBS treatment by ordinary one-way ANOVA with uncorrected Fisher's LSD test as described above.
■ RESULTS
The Diameter of Encapsulating Biodegradable Particle Affects the Magnitude of Mucosal and Systemic Memory CD8 + T Cells Generated by Respiratory Immunization with an EP67-Conjugated CTL Peptide Vaccine. A threshold proportion of circulating pathogenspecific memory T cells correlates with clinical protection against influenza, measles, tuberculosis, and varicella. 3 Preclinical studies in mice also suggest that higher proportions of memory T cells can compensate by "mass action" 45 for T cell memory pools that are less responsive to subsequent infections. 46 Thus, the magnitude of the vaccine-generated memory T cell pool is an important criterion for vaccines that must generate long-lived memory T cells.
Protection against the development of HCMV disease in heart and lung transplant recipients directly correlates with the proportion of IFN-γ + polyclonal T cells specific for the human cytomegalovirus (HCMV) immediate early (IE)-1 protein. 47 The proportion of BALB/c mice that survives lethal primary Figure 1 . Diameter of encapsulating biodegradable particle affects the proportion of mucosal and systemic epitope-specific CD8 + T cells generated by respiratory immunization with an EP67-conjugated CTL peptide vaccine. A protective MCMV CTL epitope in BALB/c mice, pp89, was individually conjugated to the N-terminal of EP67 through a lysosomal protease-labile double arginine (RR) linker (pp89-RR-EP67). (A) Vehicle alone (PBS), unencapsulated pp89-RR-EP67 (Free, 50 μg), or the same dose of pp89-RR-EP67 encapsulated in ∼5.4 μm PLGA 50:50 microparticles (MP) or ∼350 nm PLGA 50:50 nanoparticles (NP) was then administered to naive female BALB/c mice (∼4 weeks old) (50 μL i.n.) on day 0 and day 7. Twenty-one days after immunization (day 28), the average percent of CD8a + CD44 Hi cells that were Tet-pp89 + ± SD (n = 4 mice) in the (B) lungs and (C) spleen was determined by flow cytometry and then compared by ordinary one-way ANOVA with uncorrected Fisher's LSD test. Data are representative of at least two independent experiments. 39 Thus, pp89-specific CD8 + T cells in BALB/c mice are a relevant model for determining the effect that encapsulating EP67-conjugated peptide vaccines in nanoscale formulations has on the magnitude of the CD8 + T cell memory pool generated by immunization.
Molecular Pharmaceutics
To determine if encapsulation and/or the diameter of encapsulating nanoscale biodegradable particle affects the magnitude of mucosal and systemic memory CD8 + T cells generated by respiratory immunization with an EP67-conjugated CTL peptide vaccine, we first covalently conjugated pp89 to the N-terminal of EP67 through a lysosomal proteaselabile double arginine linker (pp89-RR-EP67) during peptide synthesis. Conjugating EP67 to CTL epitopes through a double arginine linker increases the generation of epitope-specific CD8 + T cells by presumably increasing the proteolytic release of CTL epitopes during endosomal trafficking within EP67-activated DCs. 40 We next intranasally administered vehicle alone (PBS), unencapsulated pp89-RR-EP67 (Free), or pp89-RR-EP67 encapsulated in ∼5.4 μm PLGA 50:50 microparticles (MP) or ∼350 nm PLGA 50:50 nanoparticles (NP) ( Table 1) to naive female BALB/c mice in a volume of PBS (50 μL) expected to deliver vaccine to the nasal cavity and lungs (i.e., respiratory immunization). 43 We then compared the proportion of mucosal (lungs) and systemic (spleen) CD8a + CD44
Hi Tet-pp89 + cells in total CD8a + T cells by flow cytometry 21 days after immunization ( Figure 1A ) when the majority of remaining pp89-specific CD8 + T cells likely represent the memory pool. 48 Cells were additionally gated for CD44
Hi staining to include both baseline CD8 + T cell precursors and immunogen-experienced pp89-specific CD8 + T cells. Figure 1B ) and by 0.3% in the spleen ( Figure 1C) . Thus, encapsulating an EP67-conjugated CTL peptide vaccine in biodegradable particles between at least ∼5.4 μm and ∼350 nm in diameter and decreasing the diameter from ∼5.4 μm to ∼350 nm increases the magnitude of mucosal and systemic memory CD8 + T cells generated 21 days after respiratory immunization. The Diameter of Encapsulating Biodegradable Particle Partially Changes CD127/KLRG1 Memory Subsets of Mucosal but Not Systemic CD8 + T Cells Generated by Respiratory Immunization with an EP67-Conjugated CTL Peptide Vaccine. Although the magnitude is a fundamental characteristic of the T cell memory pool, it does not reflect the full potential of other T cell characteristics that are important for vaccine efficacy. 32 One such critical characteristic is the ability to generate long-lived protective adaptive immune responses given that the time and frequency of pathogen exposure is unpredictable and/or asymptomatic for some pathogens.
A well-established memory subset of CD8 + T cells associated with long-lived survival is based on the relative cell surface expression of CD127 (IL-7Rα) that correlates with the intracellular expression of antiapoptotic genes mediated through IL-7 signaling and KLRG1 that correlates with replicative senescence. 50 53 There is also evidence from an Listeria monocytogenes-OVA challenge model in mice that DPEC represent a pool of "intermediate-lived" cells (vs shortlived SLEC and long-lived MPEC) that rapidly expand into EEC after subsequent infections and contract back into DPEC after infection is resolved. 57 To determine if the diameter of encapsulating biodegradable particle affects CD127/KLRG1 memory subsets of mucosal and Tet-pp89 + cells), EEC (∼18%), SLEC (∼2%), and DPEC (∼0.1%) in the spleen (not shown). Thus, decreasing the diameter of encapsulating biodegradable particle from ∼5.4 μm to ∼350 nm changes CD127/KLRG1 subsets of mucosal but not systemic memory CD8 + T cells 21 days after respiratory immunization with an EP67-conjugated CTL peptide vaccine.
The Diameter of Encapsulating Biodegradable Particle Changes CD127/KRLG1/CD62L Memory Subsets of Systemic CD8 + T Cells Generated by Respiratory Immunization with an EP67-Conjugated CTL Peptide Vaccine. Although no differences in CD127/KLRG1 CD8 + T cell subsets were observed between NP and MP in the spleen (not shown), these subsets can further differentiate into effector and central memory subsets based on the expression of the lymph node-homing cell adhesion molecule, CD62L. 53 54 All three subsets release effector cytokines such as IFN-γ, but TEFF cells have the highest cytolytic potential in vitro, followed by TEM cells. 60 Furthermore, the functional contributions of TCM and TEM against secondary viral challenge are dependent on the nature of the pathogen, route of infection, and model system. 58, 59 Thus, it is likely that the most important T cell subsets for viral protection depend on the host and/or the pathogen. (Figure 3A ), ∼10% more with a TEM cell surface phenotype (CD127 + KLRG1 − CD62L − ) ( Figure 3B ), but ∼16% less with a TCM cell surface phenotype (CD127 + KLRG1 − CD62L + ) than MP ( Figure 3C ). Thus, decreasing the diameter of encapsulating biodegradable particle from ∼5.4 μm to ∼350 nm potentially changes CD127/ KLRG1/CD62L memory subsets of systemic CD8 + T cells 21 days after respiratory immunization with an EP67-conjugated CTL peptide vaccine.
The Diameter of Encapsulating Biodegradable Particle Changes Epitope-Responsive Subsets of Mucosal and Systemic CD8 + T Cells Generated by Respiratory Immunization with an EP67-Conjugated CTL Peptide Vaccine. In addition to memory subsets based on the expression of cell surface markers (i.e., surface phenotype), functional memory subsets of CD8 + T cells can be based on the release of cytokines after exposure to protective epitopes such as pp89 for MCMV (i.e., epitope-responsiveness). 32 For CD8 + T cells, the secretion of IFN-γ, TNF-α, and/or IL-2 is critical Figure 3 . Diameter of encapsulating biodegradable particle affects CD127/KRLG1/CD62L memory subsets of systemic CD8 + T cells generated by respiratory immunization with an EP67-conjugated CTL peptide vaccine. Twenty-one days after respiratory immunization of naive female BALB/c mice (∼4 weeks old) with pp89-RR-EP67 encapsulated in ∼5.4 μm PLGA 50:50 microparticles (MP) or ∼350 nm PLGA 50:50 nanoparticles (NP) (Figure 1) , the average percent of CD8a + CD44 Hi Tet-pp89 + cells ± SD (n = 4 mice) in the spleen that were (A) effector cells (TEFF: for their effector function in vivo and may identify functional subsets of CD8 + T cells that correlate more closely with protection against a given pathogen. 32 To determine if the diameter of encapsulating biodegradable particle changes epitope-responsive subsets of mucosal and systemic CD8 + T cells generated by respiratory immunization with an EP67-conjugated CTL peptide vaccine, we again administered vehicle alone, unencapsulated pp89-RR-EP67, or pp89-RR-EP67 encapsulated in MP (∼4.5 μm) or NP (∼350 nm) (Table 1) Figure 4A ) and CD8 + TNF-α + cells in the spleen ( Figure 4B ) to a greater extent than unencapsulated pp89-RR-EP67 (Figure 4 , light gray bars) and vehicle alone (Figure 4, PBS) . Furthermore, NP increased the proportion of pp89-responsive CD8 + IFN-γ + cells in the lungs above MP ( Figure 4A , black bar vs dark gray bar), whereas MP increased the proportion of pp89-responsive multifunctional CD8
+ TNF-α + IL-2 + cells in the spleen above NP ( Figure 4B ). Thus, decreasing the diameter of encapsulating biodegradable particle from ∼5.4 μm to ∼350 nm changes epitope-responsive subsets of mucosal and systemic CD8 + T cells generated 21 days after respiratory immunization with an EP67-conjugated CTL peptide vaccine.
Encapsulation in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization with an EP67-Conjugated CTL Peptide Vaccine. Encapsulation in nanoscale biodegradable particles increases the generation of CD8 + T cell responses after mucosal immunization by increasing uptake by mucosa-associated lymphoid tissue (MALT) and APCs and subsequent cross presentation to MHC I. 61 Furthermore, we found that respiratory immunization with an EP67-based CTL peptide vaccine that included pp89-RR-EP67 increases protection of naive BALB/c mice against primary respiratory challenge with MCMV and corresponded, in part, with an increase in pp89-specific CD8 + T cells. 38 Thus, encapsulation is expected to increase the efficacy of mucosal immunization with pp89-RR-EP67 against primary respiratory challenge with MCMV and possibly be affected by particle diameter through differences in the total magnitude or CD127/KLRG1/CD62L memory subsets of pp89-specific CD8 + T cells. To determine if the diameter of the encapsulating biodegradable particle affects protection against primary respiratory infection with MCMV after respiratory immunization with an EP67-conjugated CTL peptide vaccine, we again administered vehicle alone (PBS), unencapsulated pp89-RR-EP67, or pp89-RR-EP67 encapsulated in MP or NP (Table. 1) to naive female BALB/c mice under the same dosage regimen ( Figure 1A ). We then administered sublethal titers of single mouse-passaged salivary gland-derived MCMV (P1-SGV) intranasally 21 days postimmunization in a volume of PBS expected to deliver P1-SGV to the nasal cavity and lungs (i.e., respiratory challenge) and compared peak titers of productive MCMV in the salivary glands 14 days postinfection by plaque assay ( Figure 5A ). We focused on protection of the salivary glands because it likely acts as a viral reservoir for the horizontal transmission of CMV. Thus, encapsulating an EP67-conjugated CTL peptide vaccine in biodegradable particles between ∼5.4 μm to ∼350 nm in diameter increases the efficacy of respiratory immunization against primary respiratory infection with MCMV but is unaffected by particle diameter under the current experimental conditions.
■ DISCUSSION
Our study provides evidence that decreasing the diameter of the encapsulating biodegradable particle from ∼5.4 μm to ∼350 nm potentially affects not only the total magnitude but also surface phenotype and epitope-responsive memory subsets of mucosal and systemic CD8 + T cells generated by respiratory immunization with an immunostimulant-conjugated CTL peptide vaccine. We found that, 21 days after respiratory immunization of naive female BALB/c mice with the MCMV CTL peptide vaccine pp89-RR-EP67, decreasing the diameter of encapsulating PLGA 50:50 particles from ∼5.4 μm to ∼350 nm (i) increased the magnitude of pp89-specific CD8 + T cells in the lungs and spleen (Figure 1 . Diameter of encapsulating biodegradable particle affects epitope-responsive subsets of mucosal and systemic CD8 + T cells generated by respiratory immunization with an EP67-conjugated CTL peptide vaccine. Naive female BALB/c mice (∼4 weeks old) were immunized on day 0 and day 7 by respiratory administration (50 μL i.n.) of vehicle alone (PBS), unencapsulated pp89-RR-EP67 (Free), or pp89-RR-EP67 encapsulated in ∼5.4 μm PLGA 50:50 microparticles (MP) or ∼350 nm PLGA 50:50 nanoparticles (NP) as described ( Figure 1 ). Twenty-one days after immunization (day 28), the average percent of pp89-responsive CD8a + cells ± SD (n = 4 mice) in the (A) lungs and (B) spleen normalized to treatment with media alone was determined by ICS after incubating lymphocytes or splenocytes from each treatment group with media alone or media containing pp89 for 6 h and then compared by ordinary one-way ANOVA with uncorrected Fisher's LSD test where *P < 0.05 and **P < 0.01. Data are representative of at least two independent experiments. Figure 4 ). Our study also provides evidence that encapsulation in nanoscale biodegradable particles increases the efficacy of primary respiratory immunization with an EP67-conjugated CTL peptide vaccine against primary respiratory infection with MCMV but is unaffected by decreasing the diameter of the encapsulating biodegradable particle from ∼5.4 μm to ∼350 nm under the current experimental conditions. We found that although primary respiratory immunization against pp89-RR-EP67 encapsulated in ∼5.4 μm PLGA 50:50 MP or ∼350 nm PLGA 50:50 NP decreased peak titers of productive MCMV in the salivary glands ∼10-fold and ∼20-fold, respectively, below unencapsulated pp89-RR-EP67 after primary respiratory challenge with P1-SGV, there was no statistical difference between NP and MP ( Figure 5B ). There are at least three possible reasons why decreasing the diameter of the encapsulating biodegradable particle from ∼5.4 μm to ∼350 nm does not increase protection against primary respiratory infection with MCMV. The first possibility is that the difference in the total magnitude of pp89-specific CD8 + T cells generated by NP vs MP was not sufficient to increase protection to detectable levels against productive MCMV in the salivary glands despite observed differences in memory subsets. This is supported by observations that that a higher magnitude of memory T cells can compensate by "mass action" 45 for T cell memory pools that are less responsive to subsequent infections. 46 The second possibility is that the same number of the most protective memory subsets of CD8 + T cells against MCMV infection were generated to similar levels by MP and NP despite differences in total magnitude. This is supported by evidence that adoptive transfer of epitope-specific TCM including pp89 is the most effective against primary infection with MCMV 64 and our observation that NP increased the magnitude of pp89-specific CD8 + T cells above MP in the spleen (0.81% vs 0.61%) ( Figure 1B ) but had the same levels of total TCM (CD127 + KLRG1 − CD62L + ) (∼0.38% of total CD8a + CD44 HI Tet-pp89 + cells; NP, ∼45.9% of 0.81%, and MP, ∼62% of 0.61%) ( Figure 3C ). The third possibility is that differences in protection by CD127/KLRG1/CD62L memory subsets becomes more apparent at later time points when potentially short-lived memory subsets are no longer around to provide protection. This is supported by evidence that adoptive transfer of a mixture of epitope-specifi c TEM ( ) stably protects C576BL/6 mice against multiple challenges with MCMV over the course o f 1 8 0 d a y s m o r e e ff e c t i v e l y t h a n T E F F (CD8 + CD44 HI CD127 LO ) 65 and our own observation that NP and MP generated different proportions of TEFF and TEM/ TCM (Figure 3) .
Ideal Diameter for Encapsulation in Nanoscale Biodegradable Particles? Similar to our studies, decreasing the diameter of PLGA 50:50 particles coencapsulating CpG or Poly(I:C) and ovalbumin from ∼17 μm to ∼300 nm (CpG) 30 or from ∼110 μm to ∼350 nm (Poly(I:C)) 31 increases the magnitude of memory CD8 + T cells in mice after systemic (subcutaneous) immunization. Furthermore, decreasing the diameter of poly(sebacic anhydride) [poly(SA)] particles from ∼2.5 μm to ∼470 nm or ∼360 nm increases the rate of deposition in the respiratory tract of mice after i.n. administration in 50 μL of PBS. 66 This suggests that encapsulation in biodegradable particles within the ∼300 nm diameter range is ideal for maximizing the magnitude of the memory CD8
+ and possibly CD4 + T cell pool generated by systemic or mucosal immunization. It is likely, however, that the magnitude of the memory pool will continue to increase at diameters below 300 nm to some lower limit because decreasing the diameter of polypropylene sulfide particles from 200 to 30 nm decreases the magnitude of epitope-specific CD4 + T cells in the lungs against conjugated OVA after i.n. administration. 67 In contrast to CD8 + T cells, decreasing the diameter of encapsulating biodegradable particle from 8 μm to <2 μm 68 decreases the generation of serum IgG after systemic immunization, and decreasing the diameter from 4 μm to 600 nm, 69 14 μm to 4 μm, 70 or 1 μm to 200 nm 71 decreases the generation of serum IgG against encapsulated protein after oral or intranasal immunization, respectively. This suggests that the ideal encapsulating diameter for antibodies is in the micrometer range. Furthermore, it remains to be determined whether similar trends with particle diameters occur in larger animal models or humans and will require tight control over the distribution of particle diameters as well as the use of the most effective diameter characterization techniques. 29 There is also evidence that the surface chemistry of the particle can affect the rate of uptake by human dendritic cells in vitro. 72 As such, identifying the optimal diameter for this dosage form will ultimately depend on how it affects the required protective immune response(s) against a specific pathogen in a given host, tight control and characterization of particle diameter, and possible confounding effects by the surface chemistry and composition of the encapsulating particle.
Possible Role of the Diameter of Encapsulating Biodegradable Particle in the Magnitude and Memory Subsets of CD8 + T Cells Generated by Respiratory Immunization with an EP67-Conjugated CTL Peptide Vaccine. In a murine model that closely resembles immunization with subunit vaccines, the process of T cell expansion and memory formation consists of three phases that begin when naive T cells enter lymph nodes (LN) containing activated DCs that have a high level of epitope presentation in MHCI (pMHCI). The transition from phase 1 to phase 2 is required for eventual sustained T cell expansion and the development of long-lived memory T cells. 74 At very low pMHCI surface densities on activated DCs, T cells rapidly expand but do not progress to phase 2 and eventually rapidly contract within 96 h, whereas increasing the number of LPS-activated DCs per LN and surface density of pMHCI per activated DC increases the rate of transition from phase 1 to phase 2. 75 Thus, although not directly investigated, intermediate numbers of activated DCs per LN and pMHCI surface densities per activated DC likely have effects on the magnitude of the T cell pool and, possibly, the proportions of memory subsets. The process of memory T cell development is also affected by the cytokine microenvironment and presence of Th cells and neutrophils in secondary lymphoid organs. 59, 76 As such, it is possible that encapsulation in NP or MP ultimately affects the total magnitude and memory subsets of mucosal and systemic CD8 + T cells generated by mucosal immunization through different effects on the magnitude and kinetics of activated DC-pMHCI/surface densities of pMHCI as well as the cytokine microenvironment in MALT-draining LN and the spleen.
With the above model in mind, NP may increase the total magnitude of the mucosal and systemic CD8 + T cell memory pool (day 21 postimmunization for this study) over MP, in part, by first increasing the rate at which encapsulated pp89-RR-EP67 localizes to the MALT and spleen. This is supported by observations that (i) decreasing the diameter of poly(SA) particles from 2.5 μM to 360 nm increases deposition in the respiratory tract of mice within at least 6 h after i.n. administration in 50 μL of PBS, 63 (ii) decreasing the diameter of polystyrene particles from 2 μm to 200 nm increases the rate of NALT uptake in human adenoid tissues, 77 and (iii) both 7 μm styrene-divinylbenzene microspheres 20 and 1.1 μm polystyrene microspheres 19 translocate to the spleen after i.n.
administration in 50 μL of PBS at a rate that is likely dependent on particle diameter. After arriving in the MALT, NP may be internalized at a faster rate than MP by migrating DCs and cross-present CTL epitopes in MHCI to a greater extent and for a longer duration. A similar effect may occur with NP localizing to the spleen but through direct interactions with resident DCs. This increase in the amount of NP delivered to the draining LN and spleen and the rate of DC internalization then increases and sustains a greater number of activated DC with higher surface densities of pMHCI in MALT-draining LN and the spleen, leading to an increase in the rate of transition from phase 1 to phase 2 during T cell expansion and subsequent number of T cells that transition to the CD8 + T cell memory pool. This model is supported, in part, by observations that (i) decreasing the diameter of PLGA 50:50 particles coencapsulating CpG and OVA from 7 μm to 300 nm or PLGA 50:50 particles containing coencapsulated poly(I:C) and OVA from ∼17 μm to ∼357 nm increases the rate of internalization in a human DC cell line 30 or an immature murine dendritic cell line, 31 respectively; (ii) decreasing the diameter of PLGA 50:50 particles containing coencapsulated poly(I:C) and OVA from ∼17 μm to ∼357 nm increases MHCI presentation; 31 (iii) encapsulation of OVA in PLGA between ∼500 nm and 1 μm increases the duration of MHCI presentation in mouse bone marrow-derived dendritic cells (BMDCs) in vitro compared to soluble OVA; 17 and (iv) decreasing the diameter of polystyrene particles from 1 μm to 20 nm increases the rate of uptake by lung parenchyma DC and migrating DC in lung draining LN of mice within 24 h of i.n. administration. 78 Differential internalization by subsets of DCs and macrophages is also an additional consideration although coencapsulation of CpG and OVA in PLGA 50:50 microspheres increases cross-presentation in both cell types in vitro and in vivo. 79 Possible differences in the generation of long-term T cell memory responses by either cell type alone in vivo, however, were not determined.
Again, with the above model in mind, differences in the memory subsets between NP and MP could also be due to differences in effects on the 3-phase model of T cell expansion and the subsequent kinetics of memory development by differences in the rates of particle localization to the MALT, draining LN, and the spleen. As such, the proportions of memory subsets at 21 days postimmunization may reflect differences in the kinetics of memory development and eventually become similar at later time points.
Given that pp89-RR-EP67 alone is active after respiratory immunization 38 but unlikely to directly stimulate neutrophils in the draining LN 35 and the possibility that 2 to 8 μm particles are not phagocytosed by APCs in vivo, 80 the contributions of released vs encapsulated peptide vaccine during particle localization to the MALT-draining LN and the spleen by our 5 μm diameter MP can also not be overlooked. There is also the possibility that NP and MP have different effects on the cytokine microenvironment in MALT-draining LN and the spleen through different direct effects on macrophages and DCs. 81 
■ CONCLUSIONS
In summary, our findings indicate that the diameter of encapsulating nanoscale biodegradable particles potentially affects the total magnitude, effector/central memory subsets, and epitope-responsive subsets of mucosal and systemic epitope-specific CD8 + T cells generated by respiratory immunization with an encapsulated EP67-conjugated CTL peptide vaccine. Thus, varying the diameter of nanoscale biodegradable particles containing coencapsulated immunostimulants (conjugated or free) and subunit vaccines may increase the efficacy of mucosal vaccines against certain pathogens by selectively increasing the magnitude of one or more CD8 + T cell memory subsets that correlate the strongest with clinically defined protection.
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